ArticleJCI insight2016
Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.Cell biology and toxicology · 2024Review
- Liposomal Phenylephrine Nanoparticles Enhance the Antitumor Activity of Intratumoral Chemotherapy in a Preclinical Model of Melanoma.ACS biomaterials science & engineering · 2024Article
- Human intravital microscopy in the study of sarcomas: an early trial of feasibility.Frontiers in oncology · 2023Article
- miRNA therapeutics in precision oncology: a natural premium to nurture.Exploration of targeted anti-tumor therapy · 2022Review
- The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies.International journal of molecular sciences · 2020Review
- X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia.Molecular neuropsychiatry · 2019Article
- Aptamer Therapeutics in Cancer: Current and Future.Cancers · 2018Review
- Cell-to-cell communication: microRNAs as hormones.Molecular oncology · 2017Review
- Development of Phosphorothioate DNA and DNA Thioaptamers.Biomedicines · 2017Review
- RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- The Pleiotropic Role of L1CAM in Tumor Vasculature.International journal of molecular sciences · 2017Review
- Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.BioTechniques · 2016Article
Corrections and comments
- Erratum issued
- Expression of concern
Authors and funding
33 authors at 6 institutions in 2 countries.
Funding
Abstract
Current antiangiogenesis therapy relies on inhibiting newly developed immature tumor blood vessels and starving tumor cells. This strategy has shown transient and modest efficacy. Here, we report a better approach to target cancer-associated endothelial cells (ECs), reverse permeability and leakiness of tumor blood vessels, and improve delivery of chemotherapeutic agents to the tumor. First, we identified deregulated microRNAs (miRs) from patient-derived cancer-associated ECs. Silencing these miRs led to decreased vascular permeability and increased maturation of blood vessels. Next, we screened a thioaptamer (TA) library to identify TAs selective for tumor-associated ECs. An annexin A2-targeted TA was identified and used for delivery of miR106b-5p and miR30c-5p inhibitors, resulting in vascular maturation and antitumor effects without inducing hypoxia. These findings could have implications for improving vascular-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.